![Kimberly Graper](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kimberly Graper
Plus aucun poste en cours
Profil
Kimberly Graper worked at F2g Inc. from 2021 to 2022 as Senior Director & Corporate Controller.
Ms. Graper worked at Imunon, Inc. from 2022 to 2026 as Chief Financial & Accounting Officer from 2025 to 2026.
Ms. Graper attended Seton Hall University School of Law for graduate studies and Clemson University for undergraduate studies.
Anciens postes connus de Kimberly Graper
| Sociétés | Poste | Fin |
|---|---|---|
| IMUNON, INC. | Directeur Financier/CFO | 14/01/2026 |
F2g Inc.
 F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Comptroller/Controller/Auditor | 01/10/2022 |
Formation de Kimberly Graper
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
11
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Imunon, Inc.
 Imunon, Inc. BiotechnologyHealth Technology Engages in the provision of oncology drug development services | Health Technology |
Clemson University
 Clemson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seton Hall University School of Law
 Seton Hall University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
F2g Inc.
F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Commercial Services |
